Bioethics, COVID-19 Vaccine, Governance and Licensing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioethics

COVID-19 Vaccine

Governance

Licensing

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

SEPTEMBER 28, 2023

Such a provision could prevent the public from paying twice for publicly-funded medical products—first through their taxes subsidizing government funded research and development, and second to procure the product in an inflated U.S. pharmaceutical market. Moreover, the NASDAQ Biotechnology Index increased by 374% from 1995 to 2000.

COVID-19

COVID-19 COVID-19 Vaccine Pharmaceutical Industry Governance

The 2021 Shkreli Awards: Lown Institute Counts Down the Top 10 Healthcare Industry Abuses in the Coronavirus Pandemic

Health Populi

JANUARY 5, 2021

When he led Turing Pharmaceuticals in 2015, he acquired a license for the drug Daraprim (an anti-malarial therapy also used for HIV/AIDS), raising the drug price from $13.50 2: Moderna, funded with nearly $1 billion in taxpayer dollars to develop a COVID-19 vaccine, sets the highest prevailing market price for the product.

COVID-19

COVID-19 Public Health COVID-19 Vaccine Doctors

Health Care Compliance Brief

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

The 2021 Shkreli Awards: Lown Institute Counts Down the Top 10 Healthcare Industry Abuses in the Coronavirus Pandemic

Stay Connected